Skip to main content
An official website of the United States government

tovorafenib

View Patient Information
An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.
US brand name:Ojemda
Code name:BIIB-024
DAY 101
DAY-101
DAY101
MLN-2480
MLN2480
TAK-580
TAK580
Chemical structure:(R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide
Search NCI's Drug Dictionary